Mineralys Therapeutics, Inc.
Financials
Valuation Metrics
Mineralys Therapeutics, Inc.'s Market Cap is $2.48B. At end of 2025 it was $2.92B. Ranked #1883 of 3,121 in US market (top 60%), #699 of 1,463 on NASDAQ (top 48%), #120 of 266 in Pharmaceuticals, Biotechnology & Life Sciences (top 45%) by Market Cap.
Investment Metrics(as of 2026-09-18)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $2.48B | US#1,883/3,121 Sec#120/266 |
| Revenue | $0.00 | US#2,889/3,121 Sec#196/266 |
| Net Income | $-350M | US—/3,121 Sec—/266 |
| Total Assets | $668M | US#2,656/3,121 Sec#138/266 |
| Net Assets | $551M | US#2,167/3,121 Sec#101/266 |
| Employees | 76 | US#2,671/3,121 Sec#195/266 |
| Value | ||
| P/B | 4.50x | US#2,125/3,121 Sec#132/266 |
| FCF Yield | -5.60% | US—/3,121 Sec—/266 |
| Profitability | ||
| ROE | -63.45% | US#2,730/3,121 Sec#178/266 |
| ROA | -52.34% | US#2,998/3,121 Sec#218/266 |
| Financial Health | ||
| Debt Ratio | 21.23% | US#242/3,121 Sec#82/266 |
| Total Debt | $98M | US#2,452/3,121 Sec#121/266 |
| FCF | $-139M | US#2,703/3,121 Sec#171/266 |
| Cash | $138M | US#2,003/3,121 Sec#142/266 |
| Current Ratio | 34.46x | US#74/3,121 Sec#8/266 |
| Performance | ||
| 1Y Return | -29.72% | US#2,524/3,121 Sec#218/266 |
| 1M Return | 3.97% | US#478/3,121 Sec#51/266 |
| From 52W High | -41.20% | US#2,491/3,121 Sec#198/266 |
| 1Y MDD | -52.46% | US#2,550/3,121 Sec#190/266 |
| Trading | ||
| Volume | 3,585,870 shares | US#1,302/3,121 Sec#139/266 |
| Trading Value | $100M | US#1,577/3,121 Sec#121/266 |
| Per Share | ||
| EPS | $-3.95 | US—/3,121 Sec—/266 |
| BPS | $6.23 | US#2,176/3,121 Sec#109/266 |
Company Info
Mineralys Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on developing medicines to target diseases driven by abnormally elevated aldosterone. Its clinical-stage product candidate, lorundrostat, is a proprietary, orally administered, highly selective aldosterone synthase inhibitor that are initially developing for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone, including hypertension and chronic kidney disease. The company was founded by Brian Taylor Slingsby on May 31, 2019 and is headquartered in Radnor, PA.